Evaxion Biotech A/S announced on December 12, 2024, the establishment of a new AI-derived precision cancer vaccine concept targeting non-conventional Endogenous Retrovirus (ERV) tumor antigens. These antigens are shared across patients, offering a broader applicability for cancer vaccines.
Novel preclinical data confirmed the effectiveness of this precision vaccine approach. The studies demonstrated the induction of strong T-cell responses and significant tumor growth inhibition in mice, thereby establishing preclinical Proof-of-Concept for the program.
This new approach, enabled by Evaxion’s AI-Immunology platform, could potentially allow for the use of cancer vaccines in patients who do not respond to conventional immunotherapies. Evaxion plans to select a lead candidate for this program in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.